Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1199 results
March 2021
-
Media Release
Novartis receives EU approval for Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclerosis
There are more than 1 million people living with multiple sclerosis (MS) in Europe1, Kesimpta® (ofatumumab) addresses the current unmet need for a high-efficacy disease-modifying therapy (DMT) that… -
Media Release
Novartis expands targeted radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP)
Expands Novartis Oncology radioligand pipeline with exclusive worldwide rights to develop and commercialize therapeutic applications for a library of FAP assets including FAPI-46 and FAPI-74Broad… -
Key Release
Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer
Phase III VISION study with 177Lu-PSMA-617 met both primary endpoints, significantly improving overall survival (OS) and radiographic progression-free survival (rPFS) in patients with PSMA-positive… -
Key Release
Novartis appoints Karen Hale as Chief Legal Officer
Basel, March 22, 2021 — Novartis announced today the appointment of Karen L. Hale as Chief Legal Officer. She will report to Vas Narasimhan, M.D., CEO of Novartis and become a member of the Executive… -
Media Release
New Zolgensma data demonstrate age-appropriate development when used early, real-world benefit in older children and durability 5+ years post-treatment
Children with SMA treated presymptomatically achieved age-appropriate motor milestones including sitting, standing and walking; required no ventilatory or feeding tube support; and had no serious,… -
Key Release
Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer
Phase III CANOPY-2 trial did not meet primary endpoint of overall survival in patients with advanced or metastatic non-small cell lung cancer whose cancer progressed… -
Key Release
Novartis announces change to the Executive Committee
Shannon Klinger, Chief Legal Officer, to leave Novartis on March 15, 2021Thomas Kendris appointed Chief Legal Officer ad interimBasel, March 5, 2021 — Novartis announced today that Shannon Thyme… -
Media Release
Novartis signs initial agreement with CureVac to manufacture COVID-19 vaccine candidate
Novartis to support global supply of another COVID-19 vaccine, leveraging manufacturing capacity and capabilities to help address pandemic.Novartis plans to manufacture the mRNA and bulk drug product… -
Media Release
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
Shareholders approve 24th consecutive dividend increase to CHF 3.00 (+1.7%) per share for 2020; representing a 3.8% yield1 and approximately 63% payout of free cash flowShareholders confirm Dr. Joerg… -
Media Release
Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d’administration lors de l’Assemblée générale annuelle
Les actionnaires approuvent la 24e augmentation consécutive du dividende qui passe à CHF 3.– (+1,7%) par action pour l’année 2020, soit un rendement de 3,8%1 et une distribution du free cash-… -
Media Release
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting
Shareholders approve 24th consecutive dividend increase to CHF 3.00 (+1.7%) per share for 2020; representing a 3.8% yield1 and approximately 63% payout of free cash flowShareholders confirm Dr. Joerg… -
Media Release
Die Aktionäre von Novartis heissen an der Generalversammlung alle Anträge des Verwaltungsrats gut
Die Aktionäre bewilligen die 24. Dividendenerhöhung in Folge. Für 2020 wird die Dividende auf CHF 3.00 (+1,7%) je Aktie erhöht, was einer Rendite von 3,8%1 und einem Anteil des freien…
Pagination
- ‹ Previous page
- 1
- …
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- …
- 100
- › Next page
Test disclaimer...!!!